

Supplementary Material

Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness (VE) against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada

Supplementary Material 1 Genetic characterization of SARS-CoV-2 viruses.....	2
Supplementary Table 1: Tally of characterized study viruses, by genetic sub-group.....	4
Supplementary Figure 1: Distribution of variants of concern (VOC) among study viruses.....	5
Supplementary Figure 2. Flowchart of specimens included in VE analyses	6
Supplementary Table 2. Characteristics of vaccinated participants by vaccine type.....	7
Supplementary Table 3. Single-dose VE by approach for control selection.....	8
Supplementary Table 4. Single-dose VE by vaccine type	9
Supplementary Table 5. Single-dose VE by mRNA vaccine type	10
Supplementary Table 6. Single-dose VE by age sub-group and gender	11
Supplementary Table 7. Single-dose VE against hospitalization (including variants of concern)	12
Supplementary Table 8. Single-dose VE against infection due to variants of concern	13

Supplementary Material 1 Genetic characterization of SARS-CoV-2 viruses

To understand the mix of SARS-CoV-2 viruses underpinning vaccine effectiveness (VE) findings and to support variant-specific VE estimates, we attempted to genetically characterize all viruses collected from the 2956 cases 50-69 years old who contributed to VE analyses between epi-weeks 17 and 20 of the study period.

Viruses were genetically grouped based upon: (a) whole genome sequencing (WGS) and/or (b) real-time reverse transcription polymerase chain reaction (RT-PCR) screening assays targeting signature mutations of particular variants of concern (VOC)^{a,b,c}. Where WGS and screening RT-PCR assays were discordant, WGS results were generally accepted.

Whole genome sequencing

WGS was performed at the British Columbia Centre for Disease Control Public Health Laboratory (BCCDC PHL). In brief, SARS-CoV-2 RNA was extracted using the Applied BioSystems MagMax™ Express 96 Nucleic Acid Extractor and the MagMax Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher). Viral RNA was reverse transcribed into cDNA using Thermo SuperScript IV. A 1200bp tiled amplicon scheme^{d,e} was used to amplify the entire SARS-CoV-2 genome^f. DNA libraries were prepared using DNA Prep Library Preparation Kit (Illumina) and sequenced on a MiSeq or NextSeq 2000 instrument (Illumina, San Diego). SARS-CoV-2 whole genome consensus sequences were generated using a modified Nextflow pipeline for running the ARTIC network's^g field bioinformatics tools^h. Lineages were assigned to the respective VOC/VOI categories and their decedents using Pangolin (from version 2.4.2, pangoLEARN 2021-05-19 and up)ⁱ. Sequencing quality control metrics and mutational profiles were monitored using nCoV-tools from the Simpson Lab^j.

Screening RT-PCR

Four VOC screening RT-PCR assays were used at the BCCDC PHL and various hospital-based laboratories across the province including: (1) a laboratory-developed N501Y single nucleotide polymorphism (SNP) PCR at the Victoria General Hospital in Vancouver Island Health Authority^k; (2) a laboratory-developed N501Y and E484K dual SNP PCR at the BCCDC PHL^k; (3) a laboratory developed sequential deletion and SNP PCR including N501Y and K417T at the St. Paul's Hospital

^a Government of Canada. SARS-CoV-2 variants: National definitions, classifications and public health actions. [Accessed 29 August 2021]. Available: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/testing-diagnosing-case-reporting/sars-cov-2-variants-national-definitions-classifications-public-health-actions.html>

^b World Health Organization. Tracking SARS-CoV-2 variants. [Accessed 20 September 2021]. Available: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>

^c Center for Viral Systems Biology (CViSB), Scripps Research. SARS-CoV-2 (hCoV-19) mutation reports. Lineage | Mutation tracker. [Accessed 29 August 2021]. Available: <https://outbreak.info/situation-reports>

^d Freed NE, Vlková M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. *Biol Methods Protoc.* 2020 Jul 18;5(1):bpaa014.

^e Kuchinski KS, Nguyen J, Lee TD, et al. Mutations in emerging variant of concern lineages disrupt genomic sequencing of SARS-CoV-2 clinical specimens. *MedRxiv* 2021.06.01.21258181; (Pre-print) doi: <https://doi.org/10.1101/2021.06.01.21258181>

^f Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep.* 2021 Jan 22;70(3):95-9.

^g <https://artic.network/ncov-2019>

^h <https://github.com/BCCDC-PHL/ncov2019-artic-nf>

ⁱ Rambaut A, Holmes EC, O'Toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology* 2020;5:1403-07. Available: <https://www.nature.com/articles/s41564-020-0770-5>

^j <https://github.com/jts/ncov-tools>

^k Hogan CA, Jassem AN, Sbihi H, et al. Rapid increase in SARS-CoV-2 P.1 lineage leading to codominance with B.1.1.7 lineage, British Columbia, Canada, January-April 2021. *Emerging Infectious Diseases* 2021;27: [early release]. Doi: 10.3201/eid2711.211190. Available: https://wwwnc.cdc.gov/eid/article/27/11/21-1190_article

Laboratory in Vancouver Coastal Health Authority^a; and (4) the commercial Seegene Allplex™ SARS-CoV-2 Variant I Assay (Seegene, Seoul, South Korea) targeting N501Y and E484K at the Kelowna General Hospital Microbiology Laboratory in Interior Health Authority. Based on these methods, viruses were genetically characterized/categorized as per the algorithm below:

Alpha (Pango lineage: B.1.1.7)

WGS = B.1.1.7 or

Screening RT-PCR = Positive for N501Y and positive for 69/70 deletion or positive for N501Y and negative for E484K (presumptive)

Beta (Pango lineage: B.1.351)

WGS = B.1.351 or

Screening RT-PCR = Positive for N501Y and negative for K417T (presumptive)

Delta (Pango lineage: B.1.617.2)

WGS = B.1.617.2

Screening RT-PCR = Not established

Gamma (Pango lineage: P.1)

WGS = P.1 or

Screening RT-PCR = Positive for N501Y and positive for K417T (presumptive)

Cases with unavailable or insufficient specimen for genetic characterization were excluded. Taking into account the potentially pivotal 484K substitution and circumstances where limited mutational information could not confirm a lineage, we also excluded from variant-specific analyses:

- a. All viruses with the 484K substitution that were identified by WGS to be: (1) the Beta lineage (owing to limited number for VE estimation); or (2) not the Gamma lineage (because atypical of other variants but potentially influential on VE regardless of lineage);
- b. All viruses with the 484K substitution but missing WGS results that were: (1) 501Y positive but missing 417 SNP testing (because not possible to distinguish between Beta and Gamma variants; or (2) 501Y negative (because potentially influential on VE estimates if included as a non-VOC and not otherwise classifiable genetically);
- c. All viruses without the 484K substitution and missing WGS results that were: (1) 501Y negative (because absent WGS, unable to rule out the Delta variant or Kappa or other VOI);
- d. All viruses missing information on the 484K substitution and missing WGS results that were: (1) 501Y positive (because potentially influential on VE estimates, including among viruses with this profile not otherwise classifiable genetically as a VOC); and (2) 501Y negative (because absent WGS, unable to rule out the Delta variant or Kappa or other VOI).

Taking the above into account, remaining viruses were considered non-VOC and either variants of interest (VOI) or non-VOI^{b,c,d}, with the analysis of VE for non-VOC including non-VOI in the primary analysis but excluding non-VOI in sensitivity analysis.

The ultimate tally by genetic subgroup and final categorizations for the purpose of variant-specific VE analyses, with rationale provided in footnotes, are shown in **Supplementary Table 1** below.

^a Matic N, Lowe CF, Ritchie G, et al. Rapid detection of SARS-CoV-2 variants of concern, including B.1.1.28/P.1, British Columbia, Canada. 2021;27(6):1673-1676. doi:10.3201/eid2706.210532. https://wwwnc.cdc.gov/eid/article/27/6/21-0532_article

^b Government of Canada. SARS-CoV-2 variants: National definitions, classifications and public health actions. [Accessed 29 August 2021]. Available: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/testing-diagnosing-case-reporting/sars-cov-2-variants-national-definitions-classifications-public-health-actions.html>

^c World Health Organization. Tracking SARS-CoV-2 variants. [Accessed 20 September 2021]. Available: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>

^d Center for Viral Systems Biology (CViSB), Scripps Research. SARS-CoV-2 (hCoV-19) mutation reports. Lineage | Mutation tracker. [Accessed 29 August 2021]. Available: <https://outbreak.info/situation-reports>

Supplementary Table 1: Tally of characterized study viruses, by genetic sub-group

RT-PCR test-positive cases, VE analyses Adults 50-69 years old, epi-weeks 17-20	Categorization for Variant-specific VE Analysis	Tally (N=2956)	
Characterized and included in variant-specific VE analyses		2657 (90%)	
Total VOC		2450	
Alpha (B.1.1.7)	Alpha	1332 ^a	
Gamma (P.1)	Gamma	1017 ^b	
Delta (B.1.617.2)	Delta	101 ^c	
Total Non-VOC/non-VOI		131^c	
B.1.438.1	Non-VOC	92	
B.1.2		28	
B.1.480		5	
B.1.577		2	
B.1.438		1	
B.1.9.5		2	
AL.1		1	
Total Non-VOC/VOI		76^c	
Epsilon (B.1.429)	Non-VOC ^d	70	
Kappa (B.1.617.1)	Non-VOC ^d	6	
Characterized but excluded from variant-specific VE analyses		141 (5%)	
Genetic sub-group determined (but non-Gamma variant, 484K positive)		26	
Alpha (B.1.1.7; VOC)	Excluded	5	
Beta (B.1.351; VOC)		4 ^e	
Eta (B.1.525; Non-VOC / VOI)		11	
B.1.1.318 (Non-VOC / VOI)		4	
B.1.438.1 (Non-VOC / Non-VOI)		2	
Genetic sub-group indeterminate (and missing WGS)		115	
484K positive	Excluded	53	
501Y positive, missing 417 SNP ^f		52	
501Y negative ^g		1	
484K negative		32	
501Y negative ^h		32	
484K missing		30	
501Y positive ⁱ		17	
501Y negative ^h		13	
Not characterized and excluded: sample unavailable or insufficient		158 (5%)	

VE = vaccine effectiveness; VOC = variant of concern; VOI = variant of interest; WGS = whole genome sequencing; SNP = single nucleotide polymorphism

^a Includes 1072 characterized by WGS and another 260 presumptively characterized by screening assay.

^b Includes 903 characterized by WGS and another 114 presumptively characterized by screening assay

^c All characterized by WGS.

^d Also excluded from variant-specific VE estimation in sensitivity analyses

^e Excluded from VOC-specific VE analysis because Beta viruses were too few for that separate analysis (and also 484K positive)


^f Excluded from variant-specific VE analyses because absent information on the 417 SNP it is not possible to distinguish the Beta and Gamma variants among viruses with this profile.

^g Excluded from variant-specific VE analyses because the 484K substitution is considered pivotal and may be influential on VE if included as a non-VOC (and otherwise not classifiable genetically)

^h Excluded from variant-specific VE analyses because absent WGS, unable to rule out Delta variant or Kappa or other VOI

ⁱ Excluded from variant-specific VE analyses because the 484K substitution is considered pivotal and may be influential on VE and not otherwise classifiable genetically as a VOC


Supplementary Figure 1: Distribution of variants of concern (VOC) among study viruses, adults 50-69 years old, British Columbia (BC), Canada, epidemiological weeks 17-20



VOC = variant of concern; VOI = variant of interest; for details on genetic characterization and sub-grouping see [Supplementary Table 1](#).

^ In primary variant-specific vaccine effectiveness (VE) analyses, non-VOC analysis combines non-VOI and VOI viruses together; accordingly, their combined percentages are displayed here. In sensitivity VE analysis, the non-VOC category excluded VOIs.

Supplementary Figure 2. Flowchart of specimens from adults 50-69 years old included in vaccine effectiveness (VE) analyses, April 4 (week 14) to May 22 (week 20), 2021, British Columbia (BC), Canada



- a. Approach 1 for control selection: all negative specimens collected from individuals before the end of the analysis period or becoming a case, whichever occurs first
- b. Approach 2 for control selection: one negative specimen (the latest) collected per individual before the end of the analysis period or becoming a case, whichever occurs first
- c. Approach 3 for control selection: one randomly selected specimen collected per individual before the end of the analysis period or becoming a case, whichever occurs first
- d. Vaccinated on or before the date of specimen collection
- e. Not vaccinated on or before the date of specimen collection
- f. Vaccinated controls selected as per approach 1
- g. Vaccinated controls selected as per approach 2
- h. Vaccinated controls selected as per approach 3
- i. Unvaccinated controls selected as per approach 1
- j. Unvaccinated controls selected as per approach 2
- k. Unvaccinated controls selected as per approach 3

Supplementary Table 2. Characteristics of vaccinated participants by vaccine type, adults 50-69 years, BC, Canada

Characteristic	Vaccinated ^a participants overall		Vaccinated ^a test-positive cases		Vaccinated ^a test-negative controls ^b	
	mRNA ^c , N (%)	ChAdOx1, N (%)	mRNA ^c , N (%)	ChAdOx1, N (%)	mRNA ^c , N (%)	ChAdOx1, N (%)
Number of vaccinated participants	20 479	6979	1282	576	19 197	6403
Age group (years)						
50-59	9240 (45)	4058 (58)	602 (47)	317 (55)	8638 (45)	3741 (58)
60-69	11 239 (55)	2921 (42)	680 (53)	259 (45)	10 559 (55)	2662 (42)
Median age	61	58	60	59	61	58
Gender						
Male	8980 (44)	3559 (51)	632 (49)	329 (57)	8348 (43)	3230 (50)
Female	11 499 (56)	3420 (49)	650 (51)	247 (43)	10 849 (57)	3173 (50)
Epidemiological week of specimen collection						
14	1489 (7)	440 (6)	89 (7)	55 (10)	1400 (7)	385 (6)
15	1945 (9)	779 (11)	132 (10)	98 (17)	1813 (9)	681 (11)
16	2419 (12)	989 (14)	173 (13)	85 (15)	2246 (12)	904 (14)
17	3208 (16)	1301 (19)	208 (16)	97 (17)	3000 (16)	1204 (19)
18	3779 (18)	1391 (20)	239 (19)	123 (21)	3540 (18)	1268 (20)
19	3851 (19)	1171 (17)	266 (21)	76 (13)	3585 (19)	1095 (17)
20	3788 (18)	908 (13)	175 (14)	42 (7)	3613 (19)	866 (14)
Health authority (HA)						
Fraser (FHA)	10 963 (54)	4757 (68)	760 (59)	412 (72)	10 203 (53)	4345 (68)
Interior (IHA)	2871 (14)	324 (5)	120 (9)	21 (4)	2751 (14)	303 (5)
Northern (NHA)	674 (3)	87 (1)	56 (4)	8 (1)	618 (3)	79 (1)
Vancouver Coastal (VCHA)	4239 (21)	1462 (21)	313 (24)	125 (22)	3926 (20)	1337 (21)
Vancouver Island (VIHA)	1732 (8)	349 (5)	33 (3)	10 (2)	1699 (9)	339 (5)
Days since vaccination (DSV)						
0-13	7398 (36)	2505 (36)	762 (59)	257 (45)	6636 (35)	2248 (35)
14-20	3148 (15)	1292 (19)	179 (14)	131 (23)	2969 (15)	1161 (18)
21-27	2482 (12)	1091 (16)	94 (7)	75 (13)	2388 (12)	1016 (16)
28-34	1968 (10)	851 (12)	64 (5)	46 (8)	1904 (10)	805 (13)
35-41	1520 (7)	559 (8)	41 (3)	28 (5)	1479 (8)	531 (8)
42-55	2043 (10)	598 (9)	65 (5)	31 (5)	1978 (10)	567 (9)
56-69	1087 (5)	83 (1)	48 (4)	8 (1)	1039 (5)	75 (1)
70+	833 (4)	0	29 (2)	0	804 (4)	0
Median DSV (range)	20 (0-143)	19 (0-65)	11 (0-111)	15 (0-61)	20 (0-143)	19 (0-65)

^a Single-dose recipients only without regard to interval between vaccination and specimen collection.^b As per Approach 1 for control selection: includes all test-negative specimens.^c Profiles similar for BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) recipients and are therefore combined into a single mRNA category

Supplementary Table 3. Single-dose VE overall by approach for test-negative control selection, adults 50-69 years, BC, Canada

Interval (DSV)	Case status	By approach for selecting among repeat test-negative control specimens											
		Approach 1 (all test-negative controls)				Approach 2 (single latest test-negative control)				Approach 3 (single random test-negative control)			
		Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)	Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)	Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)
0-3	Case	174 (3)	5258	44	49	174 (3)	5258	45	50	174 (3)	5258	45	50
	Control	2107 (6)	35 358	(35, 53)	(40, 56)	1868 (6)	30 960	(36, 53)	(41, 57)	1873 (6)	31 387	(36, 53)	(41, 57)
4-7	Case	343 (6)	5258	13	18	343 (6)	5258	14	19	343 (6)	5258	14	19
	Control	2646 (7)	35 358	(2, 22)	(8, 27)	2358 (7)	30 960	(4, 24)	(8, 28)	2347 (7)	31 387	(4, 24)	(8, 28)
8-13	Case	502 (9)	5258	18	22	502 (9)	5258	20	22	502 (9)	5258	20	22
	Control	4131 (10)	35 358	(10, 26)	(14, 30)	3672 (11)	30 960	(11, 27)	(14, 30)	3665 (10)	31 387	(11, 27)	(14, 30)
0-13	Case	1019 (16)	5258	23	28	1019 (16)	5258	24	29	1019 (16)	5258	23	29
	Control	8884 (20)	35 358	(18, 28)	(23, 33)	7898 (20)	30 960	(18, 29)	(23, 34)	7885 (20)	31 387	(17, 28)	(24, 34)
14-20	Case	310 (6)	5258	50	51	310 (6)	5258	49	49	310 (6)	5258	49	49
	Control	4130 (10)	35 358	(43, 55)	(45, 57)	3560 (10)	30 960	(42, 55)	(43, 55)	3560 (10)	31 387	(42, 55)	(43, 55)
21-27	Case	169 (3)	5258	67	68	169 (3)	5258	67	67	169 (3)	5258	67	67
	Control	3404 (9)	35 358	(61, 71)	(62, 73)	2989 (9)	30 960	(61, 72)	(61, 72)	2909 (8)	31 387	(61, 72)	(61, 72)
28-34	Case	110 (2)	5258	73	73	110 (2)	5258	72	72	110 (2)	5258	72	72
	Control	2709 (7)	35 358	(67, 77)	(68, 78)	2343 (7)	30 960	(66, 77)	(66, 77)	2255 (7)	31 387	(66, 77)	(66, 77)
35-41	Case	69 (1)	5258	77	78	69 (1)	5258	76	76	69 (1)	5258	76	76
	Control	2010 (5)	35 358	(71, 82)	(71, 83)	1709 (5)	30 960	(70, 81)	(69, 81)	1655 (5)	31 387	(70, 81)	(69, 81)
≥42	Case	181 (3)	5258	73	73	181 (3)	5258	71	70	181 (3)	5258	71	70
	Control	4463 (11)	35 358	(68, 77)	(69, 77)	3700 (11)	30 960	(66, 75)	(65, 75)	3508 (10)	31 387	(66, 75)	(65, 75)
≥21	Case	529 (9)	5258	72	72	529 (9)	5258	71	70	529 (9)	5258	71	70
	Control	12 586 (26)	35 358	(69, 74)	(69, 75)	10 741 (26)	30 960	(68, 74)	(67, 73)	10 327 (25)	31 387	(68, 74)	(67, 73)

DSV = Days since vaccination, the interval in days between the date of receipt of the first mRNA dose and the date of specimen collection

Vacc = vaccinated; Unvacc = Unvaccinated; VE = vaccine effectiveness; 95% CI = 95% confidence interval

VE interpretation foremost predicated upon an interval of 21 days since vaccination (yellow highlighted row).

^a VE estimates adjusted for age group (50-59, 60-69 years); gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

Supplementary Table 4. Single-dose vaccine effectiveness by vaccine type, adults 50-69 years, British Columbia, Canada

Interval (DSV)	Case status	By vaccine type							
		mRNA products				ChAdOx1 products			
		Vaccinated N (%)	Unvaccinated N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)	Vaccinated N (%)	Unvaccinated N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)
0-3	Case	135 (3)	5258	44	47	39 (1)	5258	47	55
	Control	1610 (4)	35358	(33, 53)	(37, 56)	497 (1)	35358	(27, 62)	(37, 67)
4-7	Case	267 (5)	5258	10	13	76 (1)	5258	22	32
	Control	1990 (5)	35358	(-3, 21)	(0, 24)	656 (2)	35358	(1, 39)	(14, 47)
8-13	Case	360 (6)	5258	20	22	142 (3)	5258	13	23
	Control	3036 (8)	35358	(11, 29)	(12, 30)	1095 (3)	35358	(-4, 27)	(8, 36)
0-13	Case	762 (13)	5258	23	22	257 (5)	5258	23	33
	Control	6636 (16)	35358	(16, 29)	(12, 30)	2248 (6)	35358	(12, 33)	(23, 41)
14-20	Case	179 (3)	5258	59	60	131 (2)	5258	24	32
	Control	2969 (8)	35358	(53, 65)	(53, 66)	1161 (3)	35358	(9, 37)	(18, 43)
21-27	Case	94 (2)	5258	74	74	75 (1)	5258	50	55
	Control	2388 (6)	35358	(67, 79)	(68, 79)	1016 (3)	35358	(37, 61)	(42, 64)
28-34	Case	64 (1)	5258	77	77	46 (1)	5258	62	65
	Control	1904 (5)	35358	(71, 82)	(71, 83)	805 (2)	35358	(48, 71)	(52, 74)
35-41	Case	41 (1)	5258	81	82	28 (1)	5258	65	67
	Control	1479 (4)	35358	(75, 86)	(75, 87)	531 (1)	35358	(48, 76)	(51, 77)
≥42	Case	142 (3)	5258	75	75	39 (1)	5258	59	62
	Control	3821 (10)	35358	(70, 79)	(71, 79)	642 (2)	35358	(43, 70)	(48, 73)
≥21	Case	341 (6)	5258	76	76	188 (3)	5258	58	61
	Control	9592 (21)	35358	(73, 79)	(73, 79)	2994 (8)	35358	(51, 64)	(54, 66)

DSV = Days since vaccination, the interval in days between the date of receipt of the first mRNA dose and the date of specimen collection

VE = vaccine effectiveness; 95% CI = 95% confidence interval

VE interpretation foremost predicated upon an interval of 21 days since vaccination (yellow highlighted row).

^a VE estimates adjusted for age group (50-59, 60-69 years); gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

Supplementary Table 5. Single-dose vaccine effectiveness by mRNA vaccine type, adults 50-69 years, British Columbia, Canada

Interval (DSV)	Case status	By mRNA product											
		mRNA combined products				BNT162b2 (Pfizer-BioNTech)				mRNA-1273 (Moderna)			
		Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)	Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)	Vacc N (%)	Unvacc N	Crude VE % (95% CI)	Adjusted ^a VE % (95% CI)
0-3	Case	135 (3)	5258	44	47	100 (2)	5258	44	47	35 (1)	5258	41	47
	Control	1610 (4)	35358	(33, 53)	(37, 56)	1208 (3)	35358	(32, 55)	(35, 57)	402 (1)	35358	(17, 59)	(25, 62)
4-7	Case	267 (5)	5258	10	13	200 (4)	5258	14	16	67 (1)	5258	-8	0
	Control	1990 (5)	35358	(-3, 21)	(0, 24)	1572 (4)	35358	(1, 26)	(2, 28)	418 (1)	35358	(-40, 17)	(-30, 23)
8-13	Case	360 (6)	5258	20	22	282 (5)	5258	20	21	78 (1)	5258	20	22
	Control	3036 (8)	35358	(11, 29)	(12, 30)	2379 (6)	35358	(10, 30)	(10, 31)	657 (2)	35358	(-1, 37)	(1, 39)
0-13	Case	762 (13)	5258	23	22	582 (10)	5258	24	26	180 (3)	5258	18	23
	Control	6636 (16)	35358	(16, 29)	(12, 30)	5159 (13)	35358	(17, 31)	(19, 33)	1477 (4)	35358	(4, 30)	(10, 35)
14-20	Case	179 (3)	5258	59	60	149 (3)	5258	55	56	30 (1)	5258	72	73
	Control	2969 (8)	35358	(53, 65)	(53, 66)	2248 (6)	35358	(47, 62)	(48, 63)	721 (2)	35358	(60, 81)	(61, 81)
21-27	Case	94 (2)	5258	74	74	82 (2)	5258	71	71	12 (<1)	5258	84	84
	Control	2388 (6)	35358	(67, 79)	(68, 79)	1889 (5)	35358	(64, 77)	(64, 77)	499 (1)	35358	(71, 91)	(72, 91)
28-41 ^b	Case	105 (2)	5258	79	79	91 (2)	5258	77	78	14 (<1)	5258	86	86
	Control	3383 (9)	35358	(75, 83)	(75, 83)	2704 (7)	35358	(72, 82)	(73, 82)	679 (2)	35358	(76, 92)	(76, 92)
≥42	Case	142 (3)	5258	75	75	126 (2)	5258	75	76	16 (<1)	5258	76	74
	Control	3821 (10)	35358	(70, 79)	(71, 79)	3366 (9)	35358	(70, 79)	(71, 80)	455 (1)	35358	(61, 86)	(57, 84)
≥21	Case	341 (6)	5258	76	76	299 (5)	5258	75	75	42 (1)	5258	83	82
	Control	9592 (21)	35358	(73, 79)	(73, 79)	7959 (18)	35358	(72, 78)	(72, 78)	1633 (4)	35358	(76, 87)	(76, 87)

DSV = Days since vaccination, the interval in days between the date of receipt of the first mRNA dose and the date of specimen collection

Vacc = vaccinated; Unvacc = Unvaccinated; VE = vaccine effectiveness; 95% CI = 95% confidence interval

VE interpretation foremost predicated upon an interval of 21 days since vaccination (yellow highlighted row).

^a VE estimates adjusted for age group (50-59, 60-69 years); gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

^b Combined periods (28-34 and 35-41) owing to small sample size when stratified more finely for interval and vaccine type simultaneously, notably with the smaller sample size for the Moderna product

Supplementary Table 6. Single-dose vaccine effectiveness (≥ 21 days since vaccination) by age sub-group and gender, British Columbia, Canada

Stratum	Case status	Sample sizes		Vaccine effectiveness (VE) (95% CI)	
		Vaccinated N (%)	Unvaccinated N	Crude	Adjusted
By age sub-group^a					
50-59 years					
All vaccines	Case	275 (8)	3323	70	70
	Control	6070 (22)	22 109	(66, 73)	(66, 74)
mRNA vaccines	Case	168 (5)	3323	75	75
	Control	4427 (17)	22 109	(70, 78)	(70, 78)
BNT162b2 (Pfizer-BioNTech)	Case	154 (4)	3323	73	73
	Control	3767 (15)	22 109	(68, 77)	(68, 77)
mRNA-1273 (Moderna)	Case	14 (<1)	3323	86	85
	Control	660 (3)	22 109	(76, 92)	(75, 91)
ChAdOx1 vaccines	Case	107 (3)	3323	57	58
	Control	1643 (7)	22 109	(47, 64)	(49, 66)
60-69 years					
All vaccines	Case	254 (12)	1935	73	74
	Control	6516 (33)	13 249	(69, 77)	(70, 78)
mRNA vaccines	Case	173 (8)	1935	77	78
	Control	5165 (28)	13 249	(73, 80)	(74, 81)
BNT162b2 (Pfizer-BioNTech)	Case	145 (7)	1935	76	77
	Control	4192 (24)	13 249	(72, 80)	(73, 81)
mRNA-1273 (Moderna)	Case	28 (1)	1935	80	80
	Control	973 (7)	13 249	(71, 87)	(71, 87)
ChAdOx1 vaccines	Case	81 (4)	1935	59	64
	Control	1351 (9)	13 249	(48, 67)	(54, 72)
By gender^b					
Men					
All vaccines	Case	240 (8)	2689	72	72
	Control	5412 (24)	16 868	(68, 76)	(67, 76)
mRNA vaccines	Case	139 (5)	2689	78	77
	Control	3910 (19)	16 868	(73, 81)	(73, 81)
BNT162b2 (Pfizer-BioNTech)	Case	120 (4)	2689	76	76
	Control	3187 (16)	16 868	(72, 80)	(71, 80)
mRNA-1273 (Moderna)	Case	19 (<1)	2689	84	82
	Control	723 (4)	16 868	(74, 90)	(71, 89)
ChAdOx1 vaccines	Case	101 (4)	2689	58	58
	Control	1502 (8)	16 868	(48, 66)	(48, 66)
Women					
All vaccines	Case	289 (10)	2569	71	72
	Control	7174 (28)	18 490	(67, 74)	(69, 76)
mRNA vaccines	Case	202 (7)	2569	74	75
	Control	5682 (24)	18 490	(70, 78)	(71, 79)
BNT162b2 (Pfizer-BioNTech)	Case	179 (7)	2569	73	74
	Control	4772 (21)	18 490	(68, 77)	(70, 78)
mRNA-1273 (Moderna)	Case	23 (<1)	2569	82	82
	Control	910 (5)	18 490	(72, 88)	(73, 89)
ChAdOx1 vaccines	Case	87 (3)	2569	58	63
	Control	1492 (7)	18 490	(48, 66)	(53, 71)

^a VE estimates adjusted for gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).^b VE estimates adjusted for age (50-59 years, 60-69 years); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

Supplementary Table 7. Single-dose vaccine effectiveness (≥ 21 days since vaccination) against hospitalization, overall and by variant of concern, adults 50-69 years, British Columbia, Canada

Analysis	Case status	Sample sizes		Vaccine effectiveness (VE) (95% CI)	
		Vaccinated N (%)	Unvaccinated N	Crude	Adjusted
Overall, weeks 14-20^a					
All vaccines	Case	35 (6)	547	82	86
	Control	12586 (26%)	35358	(75, 87)	81,91
mRNA vaccines	Case	32 (6)	547	78	83
	Control	9592 (21)	35358	(69, 85)	(76, 89)
BNT162b2 (Pfizer-BioNTech)	Case	27 (5)	547	78	83
	Control	7959 (18)	35358	(68, 85)	(75, 89)
mRNA-1273 (Moderna)	Case	5 (1)	547	80	85
	Control	1633 (4)	35358	(52, 92)	(63, 94)
ChAdOx1 vaccines	Case	3 (1)	547	94	96
	Control	2994 (8)	35358	(80, 98)	(86, 99)
Overall, weeks 17-20^{b,c}					
All vaccines	Case	28 (12)	215	84	87
	Control	9871 (45)	12194	(76, 89)	(81, 91)
mRNA vaccines	Case	25 (10)	215	80	84
	Control	7122 (37)	12194	(70, 87)	(75, 90)
BNT162b2 (Pfizer-BioNTech)	Case	20 (9.0)	215	80	84
	Control	5802 (32)	12194	(69, 88)	(75, 90)
mRNA-1273 (Moderna)	Case	5 (2)	215	79	83
	Control	1320 (10)	12194	(48, 91)	(58, 93)
ChAdOx1 vaccines	Case	3 (1)	215	94	95
	Control	2749 (18)	12194	(81, 98)	(85, 99)
Alpha variant of concern, weeks 17-20^b					
All vaccines	Case	11 (12)	80	83	85
	Control	9871 (45)	12194	(68, 91)	(72, 92)
mRNA vaccines	Case	11 (12)	80	76	79
	Control	7122 (37)	12194	(56, 87)	(60, 89)
BNT162b2 (Pfizer-BioNTech)	Case	9 (10)	80	76	79
	Control	5802 (32)	12194	(53, 88)	(58, 90)
mRNA-1273 (Moderna)	Case	2 (2)	80	77	80
	Control	1320 (10)	12194	(6, 94)	(17, 95)
ChAdOx1 vaccines	Case	0	80	NE	NE
	Control	2749 (18)	12194		
Gamma variant of concern, weeks 17-20^b					
All vaccines	Case	11 (10)	94	86	89
	Control	9871 (45)	12194	(73, 92)	(78, 94)
mRNA vaccines	Case	8 (8)	94	85	88
	Control	7122 (37)	12194	(70, 93)	(76, 94)
BNT162b2 (Pfizer-BioNTech)	Case	7 (7)	94	84	88
	Control	5802 (32)	12194	(66, 93)	(74, 95)
mRNA-1273 (Moderna)	Case	1 (1)	94	90	91
	Control	1320 (10)	12194	(29, 99)	(36, 99)
ChAdOx1 vaccines	Case	3 (3)	94	86	90
	Control	2749 (18)	12194	(55, 96)	(67, 97)

^a All VE estimates adjusted for age group (50-59 years; 60-69 years); gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

^b All VE estimates adjusted for age group (50-59 years; 60-69 years); gender (men, women); epidemiological week (17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).

^c Analysis of VE against variants of concern (VOC) was restricted to weeks 17-20 when full genetic characterization of case viruses was undertaken. VE against hospitalization due to Delta lacked sufficient sample size for reliable estimation, notably by vaccine type. VE against hospitalization due to non-VOC lacked sufficient sample size for reliable estimation overall or by vaccine type.

Supplementary Table 8. Single-dose vaccine effectiveness (≥ 21 days since vaccination) by variant of concern (VOC), adults 50-69 years, epi-weeks 17-20, British Columbia, Canada

Vaccines	Case Status	Any Case, epi-weeks 17-20				Non-VOC ^{a,b}				Alpha (B.1.1.7) ^a				Gamma (P.1) ^{a,c}			Delta (B.1.617.2) ^a				
		Vac N (%)	Unvac N	Crude VE % (95%CI)	Adj ^d VE % (95%CI)	Vac N (%)	Unvac N	Crude VE % (95%CI)	Adj ^d VE % (95%CI)	Vac N (%)	Unvac N	Crude VE % (95%CI)	Adj ^d VE % (95%CI)	Vac N (%)	Unvac N	Crude VE % (95%CI)	Adj ^d VE % (95%CI)	Vac N (%)	Unvac N	Crude VE % (95%CI)	Adj ^d VE % (95%CI)
All	Case	398 (19)	1730	72 (68, 75)	74 (70, 77)	13 (9)	139	88 (80, 93)	86 (75, 92)	175 (18)	774	72 (67, 76)	74 (69, 78)	140 (19)	591	71 (65, 76)	74 (68, 78)	17 (25)	50	58 (27, 76)	74 (53, 85)
	Control	9871 (45)	12 194			9871 (45)	12 194			9871 (45)	12 194			9871 (45)	12 194			9871 (45)	12 194		
mRNA	Case	238 (12)	1730	76 (73, 79)	78 (75, 81)	11 (7)	139	86 (75, 93)	84 (71, 92)	106 (12)	774	77 (71, 81)	78 (73, 82)	73 (11)	591	79 (73, 83)	80 (74, 85)	11 (18)	50	62 (28, 80)	74 (47, 87)
	Control	7122 (37)	12 194			7122 (37)	12 194			7122 (37)	12 194			7122 (37)	12 194			7122 (37)	12 194		
BNT162b2 (Pfizer-BioNTech)	Case	203 (2)	1730	75 (71, 79)	77 (73, 80)	8 (5)	139	88 (75, 94)	86 (71, 93)	93 (11)	774	75 (69, 80)	77 (71, 81)	64 (10)	591	77 (70, 82)	79 (73, 84)	9 (15)	50	62 (23, 81)	74 (45, 88)
	Control	5802 (32)	12 194			5802 (32)	12 194			5802 (32)	12 194			5802 (32)	12 194			5802 (32)	12 194		
mRNA-1273 (Moderna)	Case	35 (2)	1730	81 (74, 87)	82 (75, 87)	3 (2)	139	80 (37, 94)	81 (39, 94)	13 (2)	774	84 (73, 91)	85 (74, 92)	9 (2)	591	86 (73, 93)	85 (71, 92)	2 (4)	50	63 (-52, 91)	73 (-14, 94)
	Control	1320 (10)	12 194			1320 (10)	12 194			1320 (10)	12 194			1320 (10)	12 194			1320 (10)	12 194		
ChAdOx1	Case	160 (8)	1730	59 (52, 65)	65 (59, 71)	2 (1)	139	94 (74, 98)	92 (66, 98)	69 (8)	774	60 (49, 69)	66 (57, 74)	67 (10)	591	50 (35, 61)	60 (48, 69)	6 (11)	50	47 (-24, 77)	73 (35, 88)
	Control	2749 (18)	12 194			2749 (18)	12 194			2749 (18)	12 194			2749 (18)	12 194			2749 (18)	12 194		

DSV = Days since vaccination, the interval in days between the date of receipt of the first mRNA dose and the date of specimen collection

Vac = vaccinated; Unvac = Unvaccinated; VOC = variant of concern; VE = vaccine effectiveness; 95% CI = 95% confidence interval; Adj = Adjusted

^a Defined as in [Supplementary Material 1](#).

^b Non-VOC estimates displayed here include variants of interest (VOI); however, excluding VOI, non-VOC estimates were similar for vaccines overall in the crude (92%; 95% CI 81, 96) and adjusted (90%; 95% CI 77, 96) [based on 96 cases: 6 (6%) vaccinated]; mRNA vaccines combined in the crude (89%; 95% CI 74, 95) and adjusted (87%; 95% CI 71, 95) [based on 96 cases: 6 (6%) vaccinated]; BNT162b2 in the crude (91%; 95% CI 75, 97) and adjusted (89%; 95% CI 69, 96)[based on 94 cases: 4 (4%) vaccinated]; and mRNA-1273 in the crude (79%; 95% CI 17, 95) and adjusted (85%; 95% CI 36, 96) [based on 92 cases: 2 (2%) vaccinated] but with insufficient sample size for this estimation for ChAdOx1 vaccines.

^c Gamma (P.1) estimates displayed here are identified by whole genome sequencing and/or are 501Y, 484K and K417T positive, excluding specimens missing information for the 417 single nucleotide polymorphism (SNP). Including the additional specimens missing the 417 SNP, VE estimates are similar for vaccines overall in the crude (70%; 95% CI: 64, 75) and adjusted (74%; 95% CI: 68, 78) [based on 765 cases: 148 (19%) vaccinated]; mRNA vaccines combined in the crude (78%; 95% CI: 73, 83) and adjusted (80%; 95% CI: 74, 84) [based on 695 cases: 78 (11%) vaccinated]; BNT162b2 in the crude (77%; 95% CI 70, 82) and adjusted (79%; 95% CI 72, 84)[based on 686 cases: 69 (10%) vaccinated]; and mRNA-1273 in the crude (87%; 95% CI 74, 93) and adjusted (86%; 95% CI 73, 93) [based on 626 cases: 9 (1%) vaccinated] and for ChAdOx1 vaccines in the crude (50%; 95% CI: 35, 61) and adjusted (60%; 95% CI: 48, 69) [based on 687 cases: 70 (10%) vaccinated].

^d VE estimates adjusted for age group (50-59, 60-69 years); gender (men, women); epidemiological week (14, 15, 16, 17, 18, 19, 20); and health authority (HA) (Fraser HA, Interior HA, Northern HA, Vancouver Coastal HA, Vancouver Island HA).